摘要

老年黃斑部病變 (age-related macular degeneration, AMD) 為一種緩慢惡化的慢性發炎疾病，該疾病成因為黃斑部的視網膜色素上皮細胞 (retinal pigment epithelial cells) 凋亡或其功能缺失，晚期AMD 可依據疾病型態分為乾性及濕性黃斑部病變。近年再生醫學蓬勃發展，再生醫學的目的為透過新的技術和材料，讓因年齡、疾病或先天性缺陷而失去或受傷的細胞、組織、器官，達到替換、再生以恢復或建立正常功能，幹細胞療法為再生醫學的其中一環，本文旨在回顧幹細胞療法用於乾性AMD 之臨床試驗之進展與趨勢。

 

ABSTRACT

Age-related macular degeneration (AMD) is a chronic inflammatory disease with a slowly progressive condition. AMD is the result of dysfunction of retinal pigment epithelial cells at the macula. In its advanced stages, the disease is classified into two types: dry and wet AMD. In recent years, regenerative medicine has developed rapidly, aiming to restore or re-establish normal function by replacing or regenerating cells, tissues, or organs that have been lost, damaged due to age, disease, or congenital defects. The approach involves new technologies and new materials. Stem cell therapy is one aspect of the regenerative medicine. This review focuses on the progress and trends in current clinical trials of stem cell therapy for dry AMD.

 

 

Submitted for publication: 2024.5.9; Accepted for publication: 2024.11.24